Table 1.
Patient characteristics and imaging data.
| Patient NO/Age/Sex | Clinical Disease Stage | Pretherapy FDG (SUV) | Pretherapy FLT (SUV) | During-therapy FLT (SUV) | Time of During-therapy FLT-PET* (Days) | Percentage Decrease in SUV for FLT | Pathologic Response to Therapy (TRG Score) | Outcome |
|---|---|---|---|---|---|---|---|---|
| 1/68/M | T2N0M0 | 6.8 | 4.9 | 2.2 | 16 | 55% | 5 | DOD |
| 2/49/M | T3N1M1 | 12.7 | 5.4 | 3.5 | 15 | 35% | ND | DOD |
| 3/60/F | T3N1M0 | 7.1 | 4.0 | 2.1 | 16 | 48% | NA | DICD |
| 4/52/M | T2N1M0 | 9.6 | 5.4 | 2.4 | 17 | 56% | 5 | AWD |
| 5/64/M | T3N0M0 | 24.7 | 6.3 | 2.5 | 16 | 60% | 3 | NED |
| 6/47/M | T2N0M0 | 10.9 | 4.1 | 2.3 | 14 | 39% | 2 | AWD |
| 7/52/F | T2N1M0 | 16.9 | 6.5 | 2.3 | 16 | 65% | 4 | NED |
| 8/51/M | T3N0M0 | 3.9 | 4.2 | 3.6 | 15 | 14% | 2 | NED |
| 9/54/M | T3N1M0 | 13.3 | 8.6 | 3.9 | 15 | 55% | 3 | AWD |
| 10/39/M | T3N0M0 | 26.3 | 10.5 | 1.2 | 15 | 89% | 5 | NED |
| 11/75M | T3N1M0 | 54.5 | 7.6 | 5.7 | 17 | 25% | 5 | NED |
| 12/40/M | T3N2M0 | 22.9 | 6.6 | 1.5 | 19 | 77% | 3 | NED |
| 13/48M | T3N0M0 | 18.5 | 4.5 | 1.5 | 18 | 67% | 3 | NED |
| 14/25/M | T3N1M0 | 14.3 | 6.8 | 1.3 | 17 | 81% | 3 | NED |
*
Days after beginning of therapy, DOD = died of disease, ND = not done (died before sugary with disease progression), NA= No tumor was available for assessment, DICD = died from intercurrent disease, NED = no evidence of disease, AWD = alive with disease.